Download Immunotherapy of Cancer and Immunodiagnosis

Immunotherapy of Cancer
and
Immunodiagnosis
Folder Title: ImmunThe
Updated: April 26, 2012
TtlImThe
Forms of Cancer Immunotherapy
• Non-Specific: Generalized, Non-AntigenSpecific Immune Activation
• Specific: Antigen-specific Response Induced
in the Mouse or Patient or Passively
Transferred in from Donor Source
ImmForm1
Forms of Cancer Immunotherapy
Active: Induced Directly in the TumorBearing Animal or in the Patient
• Can be Specific or Non Specific
Passive or Adoptive: Immunologically Active
Material Transferred into Mouse or Patient
as a Passive Recipient
• Can be Specific (Antibodies, T-Cells, Antigen-presenting
cells – Dendritic Cell Vaccines)
• Or Non-Specific (Non-specifically-activated T-Cells;
ImmForm2
Cytokines
Active Non-Specific Immunotherapy
Bacterial Extracts: Non-Specific Immune Adjuvants
• BCG: Bacillus Calmette-Guerin (Attenuated Bovine
Tuberculosis Bacterium)
• Membrane Extracts of BCG
• C Parvum: Corynebacterium parvum (related to diphtheria
bacillus)
Bacterial Endotoxins: Muramyl Dipeptide
Chemical Adjuvants:
• Levamisole
• Poly IC (Poly-inosinic-Poly-cytidyllic acid)
Cytokines: (Can be actively induced or passively transferred)
• Interferons
• Interleukin 2 (IL2)
• Tumor Necrosis Factor (TNF)
ActNot
Example of Cytokines in Immunotherpay of Cancer (Passive or Active)
Adoptive Immunotherapy of Cancers
(Passive: Donor to Recipient)
Non-Specific:
• Lymphokine-activated Killer Cells (LAK Cells)\
• Cytokines
Specific: Molecular Transfer
• Monoclonal Antibodies
Specific: Cellular Transfer
• Tumor-Infiltrating Lymphocytes (TIL Cells)
• Engineered Antigen-Presenting Cells (Dendritic
Cells)
Adoptive
Some Examples of Active, Specific
Immunotherapy
(Tumor Vaccines)
Unmodified Killed or Attenuated Tumor Cells
Unmodified Tumor Antigens
Altered Tumor Cells or Tumor Antigens
• Lipidized Tumor Antigens
• Chemically Derivatized Tumor Antigens
• "Xenogenized" Tumor Cells (Virally-infected Cells)
• Exposure of Cryptic Antigens
Antigenic Peptides from Tumor Antigens
ActSpec
Autologous Tumor Cells Vaccine for Glioblastoma Multiforme
April , 2012
50% increase in survival time (48 weeks vs 33 weeks)
Minimal side –reactions
40 Patients
http://gma.yahoo.com/brain-tumor-vaccine-shows-promiseearly-trial-160209936.html
A phase 2 multicenter trial of about 40 patients with recurrent
glioblastoma -- an aggressive brain cancer that typically kills patients
within 15 months of diagnosis -- showed that the vaccine safely
increased average survival to nearly 48 weeks, compared with about
33 weeks among patients who didn't receive the treatment. The sixmonth survival rate was 93 percent for the vaccinated group,
compared with 68 percent for 86 other glioblastoma patients, who
were treated with other therapies.
Applications of Monoclonal Antibodies
Monoclonal Antibody Diagnosis and TumorImaging
• Prostate-specific Antigen (PSA)
• Carcino-embryonic Antigen (CEA)
• Colon Carcinoma A33 Antigen
Monoclonal Antibody Targeting
• Immuno-toxins
• Monoclonal antibodies directed to tumor cell
surface markers
– Can inhibit the cancer cell function
– Can target the cancer cell for destruction by the
immune response
CxMonoAb
Imaging on Metastatic Colon Carcinoma with RadioactiveIodine-Labelled Monoclonal Ab to A33 Ag
Lloyd Old, Scientific American, August, 1996, p. 138)
SeeMets
Arm
Head
Anti-CD20 Monoclonal Antibodies in Treatment
of B-Cell Lymphoma/Leukemia
Rituxan#, Zevalin# (Yttrium 90 Radio-isotope Beta-emitter),
and Bexxar* (Iodine-131 Radio-isotope Beta and Gamma Emitter)
# IDEC Pharmaceuticals. *Corixa and Glaxo Smith Kline)
Anti-CD20
Biotechnology and Clinical Applications of Monoclonals
in Cancer Medicine: Leukemia & Lymphoma Therapy
Rituxan: IDEC Pharmaceuticals
Anti-CD20 Antibody Targeted to B-Cell Lymphoma
(Chimeric Mouse CDR's with Human V-Framework and C-regions)
Zevalin: Millennium Pharmaceuticals
Anti-CD20 for B-Cell Lymphoma with Radioactive Yttrium;
Non-Hodgkin’s Lymphoma
Bexxar:
Anti-CD20 for B-Cell Lymphoma with Radioactive Iodine
Campath:
Anti-CD52 for B-Cell Chronic Lymphocytic Leukemia
(See page 141, Immunology, 6th Edition)
MAbLeukemia
Biotechnology and Clinical Applications of Monoclonals
in Cancer Medicine: Carcinoma Therapies
Herceptin: Genentech
Anti-HER2/Neu Growth Factor Receptor in Breast Cancer
Avastin:
Antibody to Vascular-Endothelial Growth Factor Receptor
(Anti-angiogenesis Therapy)
Erbitux
Antibody to Epidermal Growth Factor Receptor
(See page 141, Immunology, 6th Edition)
MAbCarcinoma
Immunotoxins in Antibody-mediated Cancer Therapy
Class # 26! I made it!
I am still here!
Y
0 of 94
o
50%
N
50%
es
1. Yes
2. No
The Endless Mirrors
What will remain when our days are done?
What will matter when we are gone?
That we stalked the crumbled halls of power?
Were known by men long lost to time?
Famed in some forgotten hour?
Or that we wrote a song still sung?
Penned a verse that touches souls?
Shaped a cure to solace fears
To offer hope, to tarry death
for childhood’s child in endless years?
Birthed a thought that sired ten more?
Conceived a dream and passed it on?
Forged a link from gone to be,
And shined our candle in the endless mirrors
That reflect forever down the halls of time.
Tom Fondy
(See tpfondy.mysite.syr.edu
LLoyd Old, Sci. Amer.
Aug, 1996
p. 139
ImmKinds
Please send in your name under “send user data”.
Rituxin, Zevalin, Herceptin, Bexxar, Campath, Erbitux,
and Avastin are all examples of immunotherapy using
_ _ _ _ _ _ _ _ _ _.
0 of 94
With respect to the use of the Turning Point XR-Transmitter System
This response is set at anonymous. You will not be identified with your answer, only
that you are responding.
1.
2.
3.
4.
5.
This is a disaster! Forget about it!
This system is not very good. It has a long
way to go to be a useful part of Biology
courses, but it is worth working on.
The XR system is OK. It is worth keeping
and using if you can make it work better.
The system was actually pretty cool. It made
an important contribution to the standards in
BIO 501.
The use of the XR system was an exciting
advance in group communication in the
classroom.
0 of 94